Ademi LLP is investigating Graphite Bio (NASDAQ: GRPH) for possible breaches of fiduciary duty and other violations of law in its transaction with LENZ Therapeutics.
Graphite Bio stockholders are expected to own approximately 35% of the combined company and LENZ Therapeutics stockholders are expected to own approximately 65% of the combined company upon the closing of the merger. The transaction agreement unreasonably limits competing transactions for Graphite Bio by imposing a significant penalty if Graphite Bio accepts a competing bid. Graphite Bio insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Graphite Bio’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.